Terminated PHASE3 INTERVENTIONAL 2-arm NCT01479192

Fenretinide in Healthy Young Women at Genetic and Familial Risk

Breast Cancer Prevention With Fenretinide in Young Women at Genetic and Familil Risk. A Phase III Randomized Clinical Trial

Sponsor: European Institute of Oncology

Conditions High-Risk Cancer

Interventions Fenretinide Placebo

Updated 6 times since 2017 Last updated: Nov 6, 2018 Started: Dec 31, 2009 Primary completion: Dec 31, 2015 Completion: Dec 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

very low rate of patient accrual

Other terminated trials from European Institute of Oncology

See all terminations from European Institute of Oncology

This PHASE3 trial investigates High-Risk Cancer and is currently terminated or withdrawn. European Institute of Oncology leads this study, which shows 6 recorded versions since 2009 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE3
Dec 2018 — Jan 2021 [monthly]

Terminated PHASE3
Jun 2018 — Dec 2018 [monthly]

Terminated PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Terminated PHASE3

First recorded

Dec 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

European Institute of Oncology

Data source: European Institute of Oncology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Milan, Italy